Zomig zolmitriptan regulatory update

FDA approved an sNDA from AstraZeneca for Zomig zolmitriptan nasal spray to treat acute migraine with or without aura in patients ages 12-17. In 2003, the agency approved the serotonin (5-HT1B) and 5-...